Guest: Dr. Stephen Shrewsbury
Guest Bio: Dr. Shrewsbury was most recently Senior Vice President, Preclinical & Clinical Development and Chief Medical Officer of AVI BioPharma (now Sarepta Therapeutics). From 2005 until 2009, he held similar roles at Adamas Pharmaceuticals and MAP Pharmaceuticals. While at MAP, Dr. Shrewsbury lead four inhaled drug programs and took two lead candidates (in asthma and migraine) from preclinical stage to Phase III in 18 months. Prior to his experience in biotechnology, Dr. Shrewsbury spent 10 years with Glaxo and Chiron launching notable respiratory programs such as Seretide in Europe and Flovent and Advair in the US. Dr. Shrewsbury received his medical degree from the University of Liverpool, UK and spent 13 years working in the UK National Health Service before entering the pharmaceutical industry.
Dr. Steve Shrewsbury discusses the problem of mutation and how it relates to the spread of viruses such as Ebola.
Health Professional Radio
Neal: Hello, you’re listening to Health Professional Radio. I’m your host, Neal Howard. Thank you so much for listening, welcome this afternoon. We’re in studio with Dr. Stephen Shrewsbury, expert in DNA gene patch therapy and also an author. The author of “Defy your DNA” – how the new gene patch personalized medicines will help you overcome your greatest health challenges. The Ebola virus is estimated by World Health Organization, CDC and others to potentially infect as many as 1.4million people by the end of this year alone. That’s a staggering figure in its sheer speed at which this virus can begin to affect people and in its ability to mutate thereby making containment that much harder. How are you doing today Doctor?
Want continue reading? Please log-in or register to see the Full Transcript